Skip to main
ARVN
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 27%
Buy 41%
Hold 32%
Sell 0%
Strong Sell 0%

Bulls say

Arvinas Inc. demonstrates a promising outlook, supported by recent clinical data indicating a statistically significant improvement in median progression-free survival (mPFS) for its product candidate vepdegestrant in patients with ESR1 mutations compared to standard treatments. The potential for greater than four months of mPFS enhancement in this specific population positions vepdeg competitively within the monotherapy market, potentially differentiating it from existing therapies such as imlunestrant and elacestrant. Furthermore, the safety profile of the combination treatments has been validated with no dose-limiting toxicities reported, reinforcing the therapeutic potential and business prospects for Arvinas's innovative drug development.

Bears say

Arvinas Inc. faces significant challenges due to concerns regarding the efficacy of its product candidates, particularly with a lack of demonstrated benefit in the Intent-to-Treat (ITT) population, which could lead to a restricted label and hinder market potential. Additionally, uncertainties surrounding the timing of clinical evidence and competitive risks from other therapies may limit opportunities for Arvinas's lead candidate, vepdegestrant, particularly as studies have not yet begun for crucial phases. The overall financial outlook reflects these challenges, with a notable reduction in price targets and a downgrade in ratings, indicating a cautious sentiment among analysts regarding the company's ability to meet revenue estimates and commercialize its pipeline effectively.

Arvinas Inc (ARVN) has been analyzed by 22 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 41% recommend Buy, 32% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 22 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jul 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.